DEEP ANALYSIS
How Wegovy and Mounjaro Reshaped the Global Pharmaceutical Landscape
As of 2025, Eli Lilly's tirzepatide portfolio (Mounjaro and Zepbound) surpassed $36.5 billion in combined sales—approximately 54 trillion won—historically outperforming Merck's (MSD) long-standing top-selling immuno-oncology drug Keytruda.
As of 2025, Eli Lilly's tirzepatide portfolio (Mounjaro and Zepbound) surpassed $36.5 billion in combined sales, amounting to approximately 54 trillion won.…
KBR Access
You've used up this month's KBR News reads
Non-members can read a limited amount of KBR News content. Sign up for free or check the membership guide to keep reading.
This month's reading: 1 / 1 used
KBR NEWSLETTER
Sign up for free and get the KBR Newsletter!
Sign up and opt in to the newsletter to receive KBR's curated business and economic insights by email.
LATEST IN TOPIC
Latest in this topic
RELATED CONTENT
Related Content
The Question More Important Than 'Is AI Eliminating Jobs?': Which Roles Are Being Redesigned?
FreeThe Pace of AI Hacking and Corporate Tasks for Response, Viewed Through Commercial Bank Hacking Incidents
FreeHow to Question and Judge in the Era of AI: Differences in AI Usage Revealed by Public Research
FreeShorter Working Hours During Childcare: How to Redistribute Work When Replacements Cannot Be Found
